Literature DB >> 22049053

Imported acquired immunodeficiency syndrome-related histoplasmosis in metropolitan France: a comparison of pre-highly active anti-retroviral therapy and highly active anti-retroviral therapy eras.

Vincent Peigne1, Françoise Dromer, Caroline Elie, Olivier Lidove, Olivier Lortholary.   

Abstract

Histoplasma capsulatum var. capsulatum infection is rare outside disease-endemic areas. Clinical presentation and outcome of acquired immunodeficiency syndrome-related histoplasmosis are unknown in non-endemic areas with wide access to highly active anti-retroviral therapy (HAART). Retrospective analysis of cases recorded at the French National Reference Center for Mycoses and Antifungals during two decades: pre-HAART (1985-1994) and HAART (1997-2006). Clinical features and outcome of all adults with proven acquired immunodeficiency syndrome-related histoplasmosis were compared between the two periods. One hundred four patients were included (40 during the pre-HAART era and 64 during the HAART era). Diagnosis was established a mean of 62 days after onset of symptoms. One-year overall mortality rates decreased from 53% (pre-HAART era) to 22% (HAART era). Diagnosis during the pre-HAART era and an older age were the only independent factors associated with death. Histoplasmosis is a rare invasive fungal infection outside disease-endemic areas. Its prognosis improved significantly during the HAART era.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22049053      PMCID: PMC3205645          DOI: 10.4269/ajtmh.2011.11-0224

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  26 in total

Review 1.  Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature.

Authors:  L J Wheat; P A Connolly-Stringfield; R L Baker; M F Curfman; M E Eads; K S Israel; S A Norris; D H Webb; M L Zeckel
Journal:  Medicine (Baltimore)       Date:  1990-11       Impact factor: 1.889

2.  Histoplasmosis and acquired immunodeficiency syndrome: a study of prognostic factors.

Authors:  Pierre Couppié; Milko Sobesky; Christine Aznar; Saravane Bichat; Emmanuel Clyti; François Bissuel; Myriam El Guedj; Fernand Alvarez; Magali Demar; Dominique Louvel; Roger Pradinaud; Bernard Carme
Journal:  Clin Infect Dis       Date:  2003-12-04       Impact factor: 9.079

3.  Differences in histoplasmosis in patients with acquired immunodeficiency syndrome in the United States and Brazil.

Authors:  Kian Karimi; L Joseph Wheat; Patricia Connolly; Gretchen Cloud; Rana Hajjeh; Emerson Wheat; Katia Alves; Carlos da Silva Lacaz Cd; Elizabeth Keath
Journal:  J Infect Dis       Date:  2002-11-05       Impact factor: 5.226

Review 4.  Immune restoration disease after antiretroviral therapy.

Authors:  Martyn A French; Patricia Price; Shelley F Stone
Journal:  AIDS       Date:  2004-08-20       Impact factor: 4.177

5.  Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy.

Authors:  Keertan Dheda; Fiona C Lampe; Margaret A Johnson; Marc C Lipman
Journal:  J Infect Dis       Date:  2004-09-29       Impact factor: 5.226

6.  Disseminated histoplasmosis and human immunodeficiency virus type 1 infection: risk factors in Guatemala.

Authors:  L Segura; M Rojas; N Pelaez; G Shor-Posner; D RosaRe; J Moreno; W Klaskala; M K Baum
Journal:  Clin Infect Dis       Date:  1997-08       Impact factor: 9.079

7.  Leads from the MMWR. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome.

Authors: 
Journal:  JAMA       Date:  1987-09-04       Impact factor: 56.272

8.  Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia.

Authors:  Alison Morris; Robert M Wachter; John Luce; Joan Turner; Laurence Huang
Journal:  AIDS       Date:  2003-01-03       Impact factor: 4.177

9.  AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Authors:  B Ledergerber; M Egger; V Erard; R Weber; B Hirschel; H Furrer; M Battegay; P Vernazza; E Bernasconi; M Opravil; D Kaufmann; P Sudre; P Francioli; A Telenti
Journal:  JAMA       Date:  1999-12-15       Impact factor: 56.272

10.  Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected persons.

Authors:  R A Hajjeh; P G Pappas; H Henderson; D Lancaster; D M Bamberger; K J Skahan; M A Phelan; G Cloud; M Holloway; C A Kauffman; L J Wheat
Journal:  Clin Infect Dis       Date:  2001-03-26       Impact factor: 9.079

View more
  9 in total

1.  Imported African histoplasmosis in an immunocompetent patient 40 years after staying in a disease-endemic area.

Authors:  Clémence Richaud; Marie-Olivia Chandesris; Fanny Lanternier; Hélène Benzaquen-Forner; Dea Garcia-Hermoso; Capucine Picard; Emilie Catherinot; Marie-Elisabeth Bougnoux; Olivier Lortholary
Journal:  Am J Trop Med Hyg       Date:  2014-09-22       Impact factor: 2.345

Review 2.  Dimorphic fungal osteoarticular infections.

Authors:  B Rammaert; M N Gamaletsou; V Zeller; C Elie; R Prinapori; S J Taj-Aldeen; E Roilides; D P Kontoyiannis; B Brause; N V Sipsas; T J Walsh; O Lortholary
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-18       Impact factor: 3.267

3.  Synthesis and antifungal activity in vitro of isoniazid derivatives against histoplasma capsulatum var. capsulatum.

Authors:  Rossana de Aguiar Cordeiro; Francisca Jakelyne de Farias Marques; Rebecca de Aguiar Cordeiro; Marcos Reinaldo da Silva; Angela Donato Maia Malaquias; Charlline Vládia Silva de Melo; Jair Mafezoli; Maria da Conceição Ferreira de Oliveira; Raimunda Sâmia Nogueira Brilhante; Marcos Fábio Gadelha Rocha; Tereza de Jesus Pinheiro Gomes Bandeira; José Júlio Costa Sidrim
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

Review 4.  Progressive disseminated histoplasmosis in the HIV population in Europe in the HAART era. Case report and literature review.

Authors:  R Martin-Iguacel; J Kurtzhals; G Jouvion; S D Nielsen; J M Llibre
Journal:  Infection       Date:  2014-03-14       Impact factor: 3.553

5.  Serum Aspergillus galactomannan for the management of disseminated histoplasmosis in AIDS.

Authors:  Sébastien Rivière; Blandine Denis; Marie-Elisabeth Bougnoux; Fanny Lanternier; Marc Lecuit; Olivier Lortholary
Journal:  Am J Trop Med Hyg       Date:  2012-08       Impact factor: 2.345

6.  Disseminated histoplasmosis in HIV-infected patients in South America: a neglected killer continues on its rampage.

Authors:  Mathieu Nacher; Antoine Adenis; Sigrid Mc Donald; Margarete Do Socorro Mendonca Gomes; Shanti Singh; Ivina Lopes Lima; Rosilene Malcher Leite; Sandra Hermelijn; Merril Wongsokarijo; Marja Van Eer; Silvia Marques Da Silva; Maurimelia Mesquita Da Costa; Marizette Silva; Maria Calvacante; Terezinha do Menino Jesus Silva Leitao; Beatriz L Gómez; Angela Restrepo; Angela Tobon; Cristina E Canteros; Christine Aznar; Denis Blanchet; Vincent Vantilcke; Cyrille Vautrin; Rachida Boukhari; Tom Chiller; Christina Scheel; Angela Ahlquist; Monika Roy; Olivier Lortholary; Bernard Carme; Pierre Couppié; Stephen Vreden
Journal:  PLoS Negl Trop Dis       Date:  2013-11-21

Review 7.  Histoplasmosis in HIV-Infected Patients: A Review of New Developments and Remaining Gaps.

Authors:  Antoine A Adenis; Christine Aznar; Pierre Couppié
Journal:  Curr Trop Med Rep       Date:  2014-03-28

8.  HIV-associated histoplasmosis early mortality and incidence trends: from neglect to priority.

Authors:  Antoine Adenis; Mathieu Nacher; Matthieu Hanf; Vincent Vantilcke; Rachida Boukhari; Denis Blachet; Magalie Demar; Christine Aznar; Bernard Carme; Pierre Couppie
Journal:  PLoS Negl Trop Dis       Date:  2014-08-21

Review 9.  Timely Diagnosis of Histoplasmosis in Non-endemic Countries: A Laboratory Challenge.

Authors:  María José Buitrago; M Teresa Martín-Gómez
Journal:  Front Microbiol       Date:  2020-03-24       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.